DUX4 and facioscapulohumeral muscular dystrophy: Another possible reason can be due to the inherent variability in DUX4 expression and pathologies in pre-clinical murine models of FSHD [22,46], as similarly seen in FSHD patients [48], which, taken together, might reduce the effects of BBR.